SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-034575
Filing Date
2021-06-25
Accepted
2021-06-25 16:01:14
Documents
14
Period of Report
2021-06-18
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-8k_20210618.htm   iXBRL 8-K 45686
2 EX-99.1 fdmt-ex991_58.htm EX-99.1 44407
3 GRAPHIC gwe05nnmwihv000001.jpg GRAPHIC 12469
  Complete submission text file 0001564590-21-034575.txt   248190

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20210618.xsd EX-101.SCH 5836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20210618_lab.xml EX-101.LAB 19463
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20210618_pre.xml EX-101.PRE 11674
7 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-8k_20210618_htm.xml XML 3566
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 211047639
SIC: 2836 Biological Products, (No Diagnostic Substances)